The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

296 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-01-31

Study Completion Date

2023-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incidence of Rosenthal basilar vein (BVR) variants (deep venous drainage variants) was relatively increased in patients with AN-SAH compared with patients with aneurysms. However, the inclusion criteria for AN-SAH patients in these studies were different. Some studies have investigated both PAN-SAH and NPAN-SAH, while some studies have only investigated PAN-SAH patients. However, we believe that NPAN-SAH may be the bleeding caused by non-BVR variation. Although previous studies did not find any association between NPAN-SAH and BVR variants, the results in their study were different, which may be due to the limited number of cases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370

Hypertension

TERMINATED PHASE4

Nebivolol in the Supine Hypertension of Autonomic Failure

NCT01044693

Hypertension Pure Autonomic Failure Multiple System Atrophy

COMPLETED NA

Norepinephrine and Phenylephrine, Which Better for Elderly?

NCT04067817

Hypotension

UNKNOWN PHASE3

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

NCT01049009

High Blood Pressure

COMPLETED PHASE4

RCVS: The Rational Approach to Diagnosis and Treatment

NCT03150524

Reversible Cerebral Vasoconstriction Syndrome

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subarachnoid Hemorrhage, Aneurysmal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nimodipine and euvolemia

administered nimodipine to prevent vasospasm, and euvolemia was maintained via intravenous hydration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with negative subarachnoid hemorrhage diagnosed by DSA

Exclusion Criteria

1. In patients with aneurysms, external ventricular drainage (EVD) alone or decompression craniotomy alone or conservative treatment was performed
2. Have a history of trauma or prior brain injury (stroke, cerebral hemorrhage, etc., with associated chronic changes on CT)
3. Patients with loss of imaging data and severe comorditions prior to onset of SAH

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No